July 27, 2021

Portolano Cavallo announces the appointment of Elisa Stefanini as partner

Portolano Cavallo is pleased to announce that attorney Elisa Stefanini, who has been with the firm since 2017, has been promoted from counsel to partner. The total number of partners now rises to fourteen — seven women and seven men.

Elisa Stefanini assists Life Sciences and Healthcare players in regulatory matters such as market accessclinical trials, and promotion of drugs, medical devices, and food supplements to the public and to healthcare professionals. She also has extensive experience on digital health and telemedicine projects and all other aspects of digitalization of the Life Sciences and Healthcare sector.

Francesco Portolano, partner at Portolano Cavallo says, “In 2016 we added Life Sciences & Healthcare to our historical Digital, Media, Technology focus. Elisa’s appointment to partner is a major milestone marking the great success achieved in this area over the last five years. Thanks to Elisa and our Life Sciences group, we now represent some of the largest Italian and foreign pharmaceutical multinationals, medical device manufacturers, healthcare service providers, investors, and startups, and many others in the sector.”

Since 2019, Elisa has been included in the Legal 500 EMEA as a “Next Generation Partner” for Healthcare and Life Sciences and she is also included in Who’s Who Legal as an expert in Life Sciences (“National Leader” in the Italy guide) and Life Sciences – Regulatory (“Global Leader”).

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
December 13, 2021
The European Commission’s Medical Device Coordination Group (MDCG) endorsed a new guidance on the operational and practical implementation of Articles 13&14 and other related obligations f...
October 27, 2021
The European Commission’s Medical Device Coordination Group (MDCG) endorsed a new guidance on the applicability of MDR requirements to 'legacy devices' and 'old' devices
October 19, 2021
The European Commission’s Medical Device Coordination Group (MDCG) endorsed a new guidance on the classification of medical devices
September 29, 2021
EU pharmaceutical strategy: today the Commission launched a public consultation on the revision of the EU general pharmaceuticals legislation (open until December 21, 2021)
August 4, 2021
Clinical Trials Regulation: EMA and European Commission confirmed that the Clinical Trials Information System (CTIS) will go-live on January 31, 2022
Search by...
Search
Follow us on
Follow us on